TY - JOUR
T1 - Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease
AU - Correia, Chase S.
AU - Briones, Melissa R.
AU - Guo, Rong
AU - Ostrowski, Rochella A.
N1 - Publisher Copyright:
© 2019, International League of Associations for Rheumatology (ILAR).
PY - 2019/4/2
Y1 - 2019/4/2
N2 - This paper is to examine the relationship between anti-cyclic citrullinated peptide (anti-CCP) antibody titers and the development of interstitial lung disease (ILD) in patients with and without rheumatoid arthritis (RA). A retrospective investigation was conducted on all adult patients tested for anti-CCP between January 1, 2007, and December 31, 2012, in a university healthcare system. Patients with specified exposures or conditions known to cause ILD were excluded. The prevalence of ILD was compared between those with and without a positive CCP. The study population was then divided into four titer groups based on anti-CCP titers: negative, low titer, moderate titer, high titer. Fisher’s exact tests compared the prevalence of ILD among the anti-CCP titer groups. Multivariate logistic regression examined the association between anti-CCP and ILD while controlling for confounders. These analyses were repeated in two subgroups: a “confirmed RA” subgroup and an “unconfirmed RA” subgroup. Two thousand and thirty patients met inclusion criteria and 453 of those had confirmed RA. Progressively higher anti-CCP titer groups developed an increasingly higher prevalence of ILD (p < 0.01). When adjusting for age, tobacco, and a diagnosis of RA, higher anti-CCP titer groups continued to correlate with an increased prevalence of ILD (OR 1.47, 95% CI 1.10–1.96, p < 0.001). This study is the first to show that progressively higher anti-CCP titers correlate with increasing prevalence of ILD, even when adjusting for confounders.
AB - This paper is to examine the relationship between anti-cyclic citrullinated peptide (anti-CCP) antibody titers and the development of interstitial lung disease (ILD) in patients with and without rheumatoid arthritis (RA). A retrospective investigation was conducted on all adult patients tested for anti-CCP between January 1, 2007, and December 31, 2012, in a university healthcare system. Patients with specified exposures or conditions known to cause ILD were excluded. The prevalence of ILD was compared between those with and without a positive CCP. The study population was then divided into four titer groups based on anti-CCP titers: negative, low titer, moderate titer, high titer. Fisher’s exact tests compared the prevalence of ILD among the anti-CCP titer groups. Multivariate logistic regression examined the association between anti-CCP and ILD while controlling for confounders. These analyses were repeated in two subgroups: a “confirmed RA” subgroup and an “unconfirmed RA” subgroup. Two thousand and thirty patients met inclusion criteria and 453 of those had confirmed RA. Progressively higher anti-CCP titer groups developed an increasingly higher prevalence of ILD (p < 0.01). When adjusting for age, tobacco, and a diagnosis of RA, higher anti-CCP titer groups continued to correlate with an increased prevalence of ILD (OR 1.47, 95% CI 1.10–1.96, p < 0.001). This study is the first to show that progressively higher anti-CCP titers correlate with increasing prevalence of ILD, even when adjusting for confounders.
KW - Interstitial lung disease (ILD)
KW - Rheumatoid arthritis (RA)
KW - Rheumatology
UR - http://www.scopus.com/inward/record.url?scp=85060140641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060140641&partnerID=8YFLogxK
U2 - 10.1007/s10067-018-04421-0
DO - 10.1007/s10067-018-04421-0
M3 - Article
C2 - 30645754
AN - SCOPUS:85060140641
VL - 38
SP - 1201
EP - 1206
JO - Clinical Rheumatology
JF - Clinical Rheumatology
SN - 0770-3198
IS - 4
ER -